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Abstract 
Background: The continuation of preventive drugs for older patients with advanced cancer has come 
under scrutiny since these drugs are unlikely to achieve their clinical benefit during the patients’ 
remaining lifespan. 
 
Patients and methods: nationwide cohort study of older adults (≥65 years) with solid cancer who died 
between 2007 and 2013 in Sweden, using routinely collected data with record linkage. We calculated 
the monthly utilization and cost of preventive drugs throughout the last year before death. 
 
Results: Among 151 201 older patients who died with cancer (mean age 81.3 [SD, 8.1] years), the 
average number of drugs increased from 6.9 to 10.1. Preventive drugs were frequently continued until 
the final month of life, including antihypertensives, platelet aggregation inhibitors, anticoagulants, 
statins, and oral antidiabetics. Median drug costs amounted to $1482 (interquartile range [IQR] $700– 
$2896]) per person, including $213 (IQR $77–$490) for preventive therapies. Compared to older adults 
who died with lung cancer ($205, IQR $61–$523), costs for preventive drugs were higher among older 
adults who died with pancreatic cancer (adjusted median difference [AMD] $13, 95% CI $5–$22), or 
gynecological cancers (AMD $27, 95% CI $18–$36). There was no decrease in the cost of preventive 
drugs throughout the last year of life. 
 
Conclusion: preventive drugs are commonly prescribed during the last year of life of older adults with 
cancer and are often continued until the final weeks before death. Adequate deprescribing strategies are 
warranted to reduce the burden of drugs of limited clinical benefit near the end of life. 
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Introduction 
In high-income countries, people aged 70 years and older now account for almost two-thirds of cancer-
related deaths.1 Chronic multimorbidity has thus become the norm rather than the exception in 
oncology2, and is associated with poorer chances of survival and with a higher burden of functional 
impairments and physical symptoms.3 Multimorbidity also comes with a higher burden of long-term 
pharmacological treatments. In the United States and in Europe, about 40% of people aged 65 years or 
older use 5 or more drugs concomitantly.4,5 This polypharmacy is particularly problematic among older 
people with advanced cancer6, since the potential to develop serious drug–drug interactions is amplified 
by the use of anticancer agents and complementary medicines.7,8 Moreover, the probability of 
experiencing adverse drug reactions increases because the main pharmacokinetic parameters are 
affected not only by age but also by the physiological impact of cancer (e.g. modified drug absorption 
due to gastrointestinal symptoms or to impairments in the gut wall function, decrease in the volume of 
distribution caused by weight loss, renal impairment due to the nephrotoxicity of chemotherapy).
9,10
 
Beyond pharmacology, polypharmacy in the context of advanced cancer also raises important questions 
from a clinical and ethical viewpoint. As cancer progresses and prognosis worsens, the net benefit of 
each additional medicine gradually decreases while the risk of harm increases. This “law of diminishing 
returns” makes the continuation or initiation of long-term treatments particularly questionable for older 
patients with advanced cancer. Preventive drugs are prescribed either to avert or delay the onset of a 
disease among individuals who are considered at high risk of developing that disease in the future 
(primary prevention), or to avoid the recurrence of a condition that the patient experienced in the past 
(secondary prevention). These drugs typically need several years before the physiological and 
biological changes that they produce translate into measurable and clinically meaningful health 
outcomes. Thus, the time-until-benefit of preventive agents is often much longer than the remaining 
lifespan of older adult with serious illness.
11 Recent randomized controlled trials show that lipid- 
lowering medications can safely be deprescribed among older adults with limited life expectancy, and 
that the discontinuation of antihypertensives among individuals without cardiovascular disease is safe 
in the short term.
12,13 Other long-term treatments such as bisphosphonates retain their effect 3 to 5 years 
after their withdrawal.
14 Nevertheless, a handful of observational studies have reported that preventive 
medications are prescribed during the last year of life of patients with life-limiting disease, and have 
cast doubt upon the benefit of these treatments.
15 There is limited investigation to date of the 
continuation and discontinuation of medications throughout the last months of life and with little 
information about the costs of these medications and about potential variation across cancer types. The 
aim of the current study was therefore to evaluate the prescribing of preventive drugs throughout the 
final year of life of older adults who died with cancer across Sweden, and to estimate the direct costs 
of preventive drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
Study design and data 
This was a retrospective cohort study based on routinely collected data in Sweden, a country with a 
universal healthcare system. Data from the National Cause of Death Register were linked through 
deterministic matching to the Total Population Register, the National Patient Register, the Swedish 
Prescribed Drugs Register, the Social Services Register, and the Swedish Register of Education. The 
Regional Ethical Review Board in Stockholm approved the study. 
 
Study population 
We included older adults aged ≥65 years who died in Sweden between 2007 and 2013, as these were 
the most recent available data. Decedents were considered as eligible for inclusion if a diagnosis of 
solid cancer (International Classification of Diseases [ICD], 10th revision codes C00–C76 and C80) was 
reported either in a hospital discharge report during the last 2 years of life, or as an underlying or 
contributing cause of death. We decided a priori to exclude decedents with missing cause of death, 
those with missing drug prescription history throughout the last 6 months of life, and those who 
remained hospitalized continuously during the last 3 months before death. Older adults with 
concomitant hematological malignancies (ICD-10 codes C81–C95) were also excluded, in order to 
select a homogenous population of individuals diagnosed only with solid cancer. Previous studies 
haveindeed shown that persons with hematological malignancies experience a rapid functional decline 
at the end of life, which makes survival prediction particularly challenging. The potential for cure until 
late in the course of the disease trajectory differentiates these older patients from those dying with solid 
cancer.16,17 
 
Outcomes 
Utilization and cost of preventive drugs during the last 12 months of life were the main study outcomes. 
Preventive drugs with questionable benefit near the end of life have been identified in a recent 
systematic review of the literature15, and include drugs for diabetes, vitamins, mineral supplements, 
antithrombotic agents, antihypertensives, statins, bisphosphonates, and medications for chronic anemia. 
The list of corresponding Anatomical Therapeutic Chemical (ATC) classification codes is available in 
Supplementary eTable 1. We computed monthly exposure to specific drug classes based on data from 
the Swedish Prescribed Drugs Register, which contains detailed information about all prescription 
drugs delivered in community pharmacies in Sweden since 2005 (including drugs dispensed to nursing 
home residents, at the exception of a few facilities with their own drug storeroom). Methods for 
constructing periods of drug exposure have been presented in detail elsewhere 5,18, and are illustrated 
in eFigure 1A. Continuation of preventive drugs was calculated as the proportion of older adults who 
were still using preventive drugs during the last month before death among those exposed one year 
before, while initiation was calculated the proportion of older adults who started using preventive 
drugs during the last year of life. Drug costs were estimated through a two-step approach, as described 
in eFigure 1B. We first divided the total cost of each purchase by the number of days covered to 
obtain the average daily cost. Second, we multiplied this average daily cost by the expected number of 
days of exposure during a given month, which allowed for distributing drug costs according to the 
assumed length of exposure. This approach provides a more realistic estimate of the costs, instead of 
artificially concentrating all expenditures at the purchase date. Drug costs were standardized using the 
harmonized index of consumer prices (HICP) with 2013 as reference year in order to correct for 
inflation over time 20 and were then converted from the Swedish currency SEK into US dollars (USD) 
based on the European Central Bank average exchange rate from 1 January to 31 December 2013 to 
facilitate international 22 comparisons (1 SEK = 0.1535 USD) . 
Assessment of individual characteristics 
Sex and date of birth were extracted from the Total Population Register and cross-validated with data 
reported on study participants’ death certificates. We categorized solid malignancies into 14 distinct 
locations. Details about the corresponding ICD-10 codes are presented in eTable 2. The overall burden 
of chronic multimorbidity was measured with a recently validated tool that captures a set of 60 distinct 
chronic diseases based on different data sources (contributing causes of deaths, inpatients and 
outpatients diagnoses reported during the last 3 years of life, and specific drugs unequivocally linked 
to chronic conditions).19 Living arrangement at time of death was defined as “community” or “nursing 
home”, while the place of death was reported as either “hospital” or “usual place of living”. The 
decedents’ level of education was categorized into “primary”, “secondary”, and “tertiary” education in 
accordance with the International Standard for Classification of Education. 
 
Statistical analysis 
Multivariable quantile regressions were used to model drug costs across different cancer types, while 
controlling for sex, age, number of chronic diseases, living arrangement, and level of education. While 
linear regression allows for modeling the mean of an outcome, quantile regression is used to model 
quantiles of the outcome when the distribution of the outcome is highly skewed.20 Beta coefficients 
obtained from quantile regression models can be interpreted as the adjusted median difference (AMD) 
in costs compared with the reference group, and are reported together with their 95% CIs. We compared 
the results with estimates drawn from generalized linear models with log link function and gamma 
distribution, to ensure that the average median effects reported in our study are concordant (in both 
direction and magnitude) with average mean effects.21 Variations in the cost of preventive drugs were 
then represented graphically in a series of contour graphs plotting the average cost by age at death and 
number of comorbidities. Two sets of sensitivity analyses were performed to mitigate the risk of bias 
due to the potentially unpredictable time of death of older adults with cancer, which would explain why 
preventive drugs were continued until the very end of life: we first excluded patients whose underlying 
cause of death suggested an acute and sudden fatal event (eTable 4); we then stratified the main analyses 
according to the time between cancer diagnosis and death, separating decedents who were diagnosed 
more than 12 months before death from those who were diagnosed during the last 6 months of life. 
Individuals with missing data for the time between diagnosis and death (n=7863, 5.2%) were excluded 
from this sensitivity analysis. Statistical analyses were performed using JMP version 13.0 (SAS 
Institute Inc) and Stata version 14.1 (StataCorp LP). This study adheres to the RECORD guidelines 
(Supporting file).
22
 
 
Results 
Characteristics of the study population 
Among a total of 165 821 older adults who died with cancer in Sweden between 2007 and 2013, 151 201 
(91.2%) met our eligibility criteria (Figure 1). Mean age at time of death was 81.3 years (SD, 8.1), 45% 
of decedents were women, 18% lived in nursing home facilities, and 47% died in hospitals. As shown 
in Table 1, the most common cancer types affected male genital organs (17%), respiratory organs 
(12%), and colon-rectum (11%). A large majority of patients had been diagnosed with cancer more than 
12 months (60%), or between 6 to 12 months (12%) before death. Hypertension, ischemic heart disease, 
heart failure, atrial fibrillation, and type 2 diabetes were the most commonly diagnosed comorbidities. 
Older adults who died without cancer reported as cause of death on their death certificate (n=29 984, 
19.8%) were, on average, older, lived more often in nursing homes, and had a greater number of chronic 
comorbidities than those who died from cancer (eTable4). 
 
Use of preventive drugs 
Throughout the last year of life, the mean number of prescribed drugs increased from 6.9 to 10.1 (mean 
difference 2.1, 95% CI 2.0–2.2) and the proportion of individuals using ≥10 drugs rose from 26% to 
52%. Preventive drugs were frequently prescribed near the end of life (Table 2). Antihypertensives were 
prescribed to 60.1% of the decedents during their last month of life, including beta-blockers (38.2%), 
angiotensin-converting-enzyme inhibitors (18.5%), and calcium channel blockers (15.9%). 
Antithrombotic agents, anti-anemics, lipid-lowering drugs, mineral supplements, and drugs for diabetes 
were also commonly prescribed. We observed little change in the use of preventive drugs over the 
course of the last year before death. The proportion of older adults who continued therapy until the final 
month of life ranged from 56.6% for bisphosphonates, to 65% for statins and vitamins, up to ≥80% for 
insulin, beta-blockers, and vitamin B12 or folic acid. Overall, 28.2% of decedents initiated 
antithrombotic agents (including 13.4% platelet aggregation inhibitors) during their last year of life, 
23.2% initiated high-blood pressure medications (including 13.3% beta-blockers), and 4.9% started 
statins. Differences in the use of preventive drugs across cancer types are reported in eTable 5. In 
sensitivity analyses, results remained very similar after excluding individuals who died from acute and 
possibly unpredictable causes of death (eTable 6), or while comparing patients who had been diagnosed 
with cancer > 12 months before death to individuals who were diagnosed closer to death (eTable 7). 
 
Drug costs during the last year of life 
The median drug cost during the last year of life was $1482 (interquartile range [IQR] $700–$2896]) 
per person, ranging from $961 among decedents with cancers of unknown primary site, to $1811 among 
women with breast cancer, up to $3073 among men with cancers affecting male genital organs (Table 
3). After adjusting for multiple confounders, we found significantly higher costs for patients with breast 
cancer, gynecological cancers, cancers of male genital organs, and multiple solid tumors, compared 
with individuals who died with lung cancer. Median monthly drug costs increased from $80 to $153 
over the course of the last year of life, although there was significant variation according to the type of 
cancer (eTable 8). The median cost for preventive drugs during the last year of life amounted to $213 
(IQR $77–$490) in the total study population and varied across cancer types. Compared to older adults 
who died with lung cancer ($205, IQR $61–$523), those who died with pancreatic cancer (adjusted 
median difference [AMD] $19, 95% CI $7–$31), breast cancer (AMD $19, 95% CI $11–$28), and 
gynecological cancers (AMD $27, 95% CI $18–$36) had the highest costs per person. Throughout 
the last year of life, the proportion of total drug costs corresponding to preventive drugs was 20.2%; 
this proportion decreased from 20.5% during the 12th month before death to 18.5% during the last month 
before death. However, despite this relative reduction, we found an absolute increase in the costs 
owing to preventive drugs (eTable 9). Overall, costs were highest among older adults aged less than 
80 years and among those who had ≥5 chronic comorbidities, although our data shows that women 
with breast cancer had significantly higher costs for preventive drugs even with a low burden of 
chronic multimorbidity (eFigure 2). In sensitivity analyses, we found only marginal differences 
according to the time between diagnosis and death (eTable 10). 
 
 
 
Discussion 
This large nationwide study has three main findings. First, a substantial share of older adults who die 
with solid cancer continues to receive preventive drugs until the final month of life. Second, preventive 
drugs account for around one fifth of the total costs of prescribed drugs, and this proportion decreases 
only slightly as death approaches. Third, there are important differences between cancer types in the 
use and costs of preventive drugs, which can only partly be explained by age and chronic 
multimorbidity. 
 
Our study builds on previous work exploring the utilization of preventive drugs in terminally ill 
patients.23,24 In Australia, Currow et al. showed that, patients were prescribed on average 2.6 drugs for 
managing comorbid conditions at the time of palliative care referral.25 Many patients who receive 
preventive cardiovascular drugs continue to do so until the very end of life.26,27 For instance, the 
prescribing of antihypertensive agents and platelet aggregation inhibitors is commonplace among 
hospice patients with advanced cancer.28 Recent studies have also shown that polypharmacy increases 
near the end of life, which is fueled not only by symptomatic drugs but also by the continuation of 
preventive agents until the very last weeks of life.18,24 
 
The frequent continuation of long-term preventive drugs is indicative of insufficient deprescribing 
strategies at the end of life. Although the preventive drugs reported in our study are most often 
pharmacologically and clinically appropriate in the general population, their use in the context of 
limited life expectancy and palliative goals of care should be examined critically.29,30 Preventive 
medicines are not necessarily inappropriate at the end of life, as some may have palliative indications 
to avert distressing symptoms or to avoid serious complications (e.g. anticoagulants for managing 
cancer-related venous thrombosis). However, the large proportion of older adults with cancer who 
continue to receive statins, antihypertensives, vitamins and mineral supplements throughout the last 
year of life does suggest the existence of routine-based prescribing practices that contribute to low-
value care. Our finding that older adults with poor-prognosis cancers (e.g. brain, lung, liver, pancreas) 
were just as likely as those with less aggressive disease to use preventive drugs during their last month 
of life suggests that there is room for deprescribing. 
 
The question of whether drug treatments should be initiated or continued near the end of life is at the 
center of the Choosing Wisely campaign, which has been endorsed by the American Society of Clinical 
Oncology, the American Geriatrics Society, and the American Medical Directors Association. It is, for 
instance, explicitly recommended to refrain from using lipid-lowering agents in older patients with 
limited life expectancy. Evidence from a recent randomized controlled trial shows that discontinuing 
statins in this population is safe and can result in improved quality of life.12 Three components seem 
essential to reduce the burden of preventive drugs of limited benefit. First, timely physician-patient 
communication is needed to evaluate whether the prescribed treatments are concordant with the patient 
goals of care. Second, physicians should carefully consider whether the prescribed drugs are likely to 
achieve their benefit within the patients’ remaining lifetime. Third, the decision to initiate, continue or 
discontinue preventive treatments should account for the risk of the patient coming to harm. 
 
From a health economics perspective, it can be argued that drugs account for only small share of the 
total healthcare expenditure, with hospital and long-term care being the major sources of medical 
spending at the end of life. In the United States, drugs-related costs (including drugs administered 
during hospital stays) amount to around 4% of the entire medical expenditure during the last year of 
life.31 However, at the patient level, these costs are substantial and may contribute to the ‘financial 
toxicity’ of treatments, especially in countries with no universal healthcare insurance coverage.32 It is 
worth noting that drug prices are generally much lower in Europe than in the United States, owing for 
the most part to strong price regulation within the European Union. In 2017, pharmaceutical 
expenditures amounted to $1162 per capita in the United States compared with $479 in Sweden.33 
Moreover, indirect costs (e.g. cost of International Normalized Ratio-testing associated with use of 
warfarin) and induced costs (e.g. hospital expenditures caused by severe adverse drug reactions) of drug 
prescribing also contribute to the overall burden of drug costs. 
This is the first nationwide study that has explored drug utilization in the last year of life according to 
cancer type, and that has investigated the costs associated with these drugs. However, we acknowledge 
a number of limitations. First, it is possible that a fraction of patients included in the cohort died from 
sudden and totally unexpected deaths, which could explain why preventive drugs were continued until 
the time of death. Retrospective cohorts of decedents are indeed prone to confounding-by-indication 
bias and tend to underestimate the prognostic uncertainty surrounding end-of-life decisions.34 However, 
sensitivity analyses were performed in an attempt to separate sudden from non-sudden deaths, and 
showed only marginal differences regarding patterns of drug utilization at the end of life. Second, 
routinely collected data about drug dispensing do not allow for assessing whether drugs are actually 
consumed by patients, and do not provide information about dosage modifications that may occur 
between two refills. It is possible that some drugs were tapered off near the end of life, which our data 
would not reflect. Moreover, the estimations of drug costs relied on the assumption that patients used 
their treatments according to the prescribed daily dose. Although this assumption is unlikely at the 
individual level, it is reasonable to assume that, at a population level, variations from one patient to 
another cancel each other out. Also, since drugs administered during hospitalizations are not collected 
in the Swedish Prescribed Drugs Register, the costs attributable to cancer-directed therapy are largely 
underestimated. Third, although this study relies on routinely collected healthcare and administrative 
data with nationwide coverage in Sweden, the generalizability of our findings may be limited to 
countries with universal health coverage and wide access to preventive drugs. Finally, we did not assess 
appropriateness of prescribing: some preventive drugs reported in this study may in specific cases and 
for specific indications have a meaningful clinical value. For instance, the frequent use of 
bisphosphonates among women with breast cancer could stem from an effort to prevent and control 
bone metastases. 
 
Conclusion 
The use of preventive drugs in the last year of life is common among older adults with cancer, although 
there is considerable variation in use according to cancer type. In this context, the use of preventive 
drugs should be reconsidered in light of patient goals of care, values and preferences. Reducing the 
therapeutic burden in people with advanced cancer has the potential to not only reduce unnecessary 
adverse effects and improve patient quality of life, it also has the potential to reduce the financial burden 
for patients. 
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Figure 1 – Study population flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 – Characteristics of older adults who died with solid cancer in Sweden, 2007–2013 
Sex, No. (%)  
Men 83 429 (55.2) 
Women 67 772 (44.8) 
Age at time of death, years  
Mean (SD) 81.3 (8.1) 
65 to 74 years 35 690 (23.6) 
75 to 84 years 56 950 (37.7) 
85 to 94 years 52 474 (34.7) 
95 years and older 6087 (4.0) 
Level of education, No. (%)  
Primary education 71 661 (48.9) 
Secondary education 57 937 (39.5) 
Tertiary education 17 030 (11.6) 
Living arrangement, No. (%)  
Community 123 702 (81.8) 
Nursing home 27 499 (18.2) 
Place of death, No. (%)  
Usual place of living 80,439 (53.2) 
Hospital facility 70,762 (46.8) 
Primary malignancy, No. (%)  
Respiratory organs 18 435 (12.2) 
Esophagus and stomach 5014 (3.3) 
Colon-rectum 16 102 (10.6) 
Liver and intrahepatic bile duct 3711 (2.5) 
Pancreas 7808 (2.5) 
Other digestive organs 3643 (2.4) 
Breast 9920 (6.6) 
Urinary tract 10 231 (6.8) 
Male genital organs 25 642 (17.0) 
Female genital organs 6868 (4.5) 
Melanoma of skin 2651 (1.8) 
Brain and meninges 2266 (1.5) 
Unknown primary site 4030 (2.7) 
Other primary malignancy 16 502 (10.9) 
Multiple solid tumors 18 378 (12.2) 
Time between diagnosis and death, No. (%)  
More than 12 months 86 032 (60.0) 
6 to 12 months 16 440 (11.5) 
Less than 6 months 40 866 (28.5) 
  
Number of chronic comorbidities, No. (%)  
Mean (SD) 4.5 (2.8) 
0 6216 (4.1%) 
1 14 242 (9.4%) 
2 19 570 (12.9%) 
3 22 039 (14.6%) 
4 21 529 (14.2%) 
≥5 67 605 (44.7%) 
Chronic comorbidities, No. (%)  
Hypertension 66 553 (44.0%) 
Ischemic heart disease 50 896 (33.7%) 
Heart failure 42 049 (27.8%) 
Atrial fibrillation 36 584 (24.2%) 
Diabetes 31 279 (20.7%) 
Sex, No. (%)  
Cerebrovascular disease 28 730 (19.0%) 
Cataract and other lens diseases 24 388 (16.1%) 
COPD, emphysema, chronic bronchitis 22 465 (14.9%) 
Dementia 17 784 (100.0%) 
Missing values: education (n=4573, 3%), time from diagnosis to death 
(n=7863, 5.2%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 – Use of preventive drugs during the last year of life of older adults (≥65 years) with solid cancer in Sweden, 2007–2013 
 
Prevalence (n=151 201)  
Continuationb until  
the final month of life 
Initiationc during  
the last year of life 12
th month 
before death 
Last month 
before death 
 Absolute change 
 
Percent Percent   Percent points (95%CI)a  Percent (95%CI) Percent (95%CI) 
Drugs used in diabetes 14.0% 14.9%  +0.9 (0.6 to 1.2)  87.3 (86.8 to 87.7) 3.6 (3.5 to 3.7) 
Insulin and analogues 7.6% 10.0%  +2.4 (2.2 to 2.6)  89.3 (88.8 to 89.9) 4.0 (3.9 to 4.1) 
Blood glucose-lowering drugs 8.7% 7.1%  -1.6 (-1.8 to -1.4)  68.2 (67.4 to 69.0) 1.8 (1.7 to 1.9) 
Vitamins 8.2% 9.2%  +1.0 (0.8 to 1.2)  64.9 (64.1 to 65.7) 6.7 (6.6 to 6.8) 
Mineral supplements 14.7% 19.2%  +4.5 (4.2 to 4.8)  68.4 (67.7 to 69.9) 14.2 (14.0 to 14.4) 
Calcium 10.5% 11.1%  +0.6 (0.4 to 0.8)  65.7 (64.9 to 66.4) 6.5 (6.4 to 6.7) 
Potassium 4.6% 7.8%  +3.2 (3.0 to 3.4)  64.5 (63.3 to 65.6) 6.8 (6.6 to 6.9) 
Antithrombotic agents 46.6% 48.1%  +1.5 (1.1 to 1.9)  79.2 (78.9 to 79.5) 28.2 (27.9 to 28.5) 
Vitamin K antagonists 7.7% 5.6%  -2.1 (-2.3 to -1.9)  47.6 (46.7 to 48.5) 3.8 (3.7 to 3.9) 
Heparin group 2.7% 10.0%  +7.3 (7.1 to 7.5)  49.3 (47.8 to 51.9) 14.9 (14.6 to 15.9) 
Platelet aggregation inhibitors 37.7% 36.2%  -1.5 (-1.8 to -1.2)  77.4 (77.1 to 77.8) 13.4 (13.2 to 13.6) 
Drugs used in the treatment of hypertension 60.4% 60.1%  -0.3 (-0.6 to 0.0)  86.4 (86.2 to 86.7) 23.2 (22.9 to 23.6) 
Low-ceiling diuretics 6.3% 5.2%  -1.1 (-1.3 to -0.9)  61.2 (60.2 to 62.1) 1.9 (1.8 to 1.9) 
Potassium-sparing agents 7.3% 11.2%  +3.9 (3.7 to 4.1)  69.0 (68.1 to 69.9) 7.6 (7.5 to 7.8) 
Beta blocking agents 37.5% 38.2%  +0.7 (0.4 to 1.0)  82.9 (82.6 to 83.3) 13.3 (13.1 to 13.6) 
Calcium channel blockersd 18.9% 15.9%  -3.0 (-3.3 to -2.7)  68.8 (68.2 to 69.3) 4.9 (4.7 to 5.7) 
ACE inhibitors 20.3% 18.5%  -1.8 (-2.1 to -1.5)  71.8 (71.3 to 72.3) 6.6 (6.4 to 6.7) 
Angiotensin II antagonists 11.7% 9.9%  -1.8 (-2.0 to -1.6)  71.3 (70.6 to 71.9) 2.4 (2.3 to 2.4) 
Lipid modifying agents 21.5% 16.8%  -4.7 (-5.0 to -4.4)  65.0 (64.4 to 65.5) 5.4 (5.3 to 5.5) 
HMG CoA reductase inhibitors 21.0% 16.3%  -4.7 (-5.0 to -4.4)  64.9 (64.4 to 65.4) 4.9 (4.7 to 5.6) 
Bisphosphonates 4.2% 3.9%  -0.3 (-0.4 to -0.2)  56.6 (55.3 to 57.8) 2.8 (2.7 to 2.9) 
Anti-anemic preparations 25.7% 30.4%  +4.7 (4.4 to 5.0)  79.7 (79.3 to 82.1) 17.6 (17.4 to 17.8) 
Iron preparations 7.4% 11.0%  +3.6 (3.4 to 3.8)  55.8 (54.9 to 56.8) 11.1 (11.0 to 11.3) 
Vitamin B12 and folic acid 21.0% 23.2%  +2.2 (1.9 to 2.5)  82.4 (82.0 to 82.8) 8.9 (8.7 to 9.1) 
Abbreviations: CI, confidence interval; ACE, angiotensin-converting-enzyme  
a Difference in proportions 
b Proportion of older adults who received drugs during the last month before death, among those exposed 12 months before death 
c Proportion of older adults who received drugs during the last year of life, among those not exposed 12 months before death 
 
d Excluding selective calcium channel blockers with direct cardiac effects (ATC C08D) 
 
 
 
Table 3 – Drug costs during the final year of life, by cancer type 
 
Decedents, 
No. 
 
Total costs for prescription drugs, 
per capita, US$a 
 
Costs for preventive drugs, per 
capita, US$b 
 
Proportion of total drug costs 
dedicated to preventive drugs, % 
Median (P25-P75) ß (95% CI)c 
 
Median (P25-P75) ß (95% CI)c 
 Total last 
year of life 
12th month Last month 
Respiratory organs 18 435  1371 (662-2619) Ref  205 (61-523) Ref  23.6% 24.6% 21.8% 
Esophagus and stomach 5014  1145 (552-2267) -122 (-178 to -65)  199 (68-479) 6 (-4 to 16)  22.9% 28.1% 15.2% 
Colorectal 16 102  1074 (538-2107) -161 (-199 to -122)  209 (72-479) 11 (4 to 18)  26.5% 28.3% 21.1% 
Liver and intrahepatic bile duct 3711  1079 (505-2117) -224 (-288 to -161)  222 (82-514) 19 (7 to 31)  23.7% 23.9% 23.6% 
Pancreas 7808  1263 (627-2353) -47 (-94 to 1)  213 (69-520) 13 (5 to 22)  23.0% 24.8% 20.6% 
Other digestive organs 3643  1041 (500-2110) -162 (-227 to -98)  191 (65-426) -7 (-19 to 5)  12.8% 12.5% 13.0% 
Breast 9920  1811 (851-3410) 528 (482 to 575)  218 (81-528) 19 (11 to 28)  26.3% 26.5% 24.1% 
Urinary tract 10 231  1221 (626-2274) -113 (-158 to -69)  232 (93-508) 11 (3 to 19)  25.1% 26.1% 21.1% 
Male genital organs 25 642  3073 (1593-4559) 1826 (1790 to 1863)  209 (80-450) 13 (6 to 19)  13.3% 13.2% 12.7% 
Female genital organs 6868  1350 (675-2568) 39 (-12 to 91)  239 (86-573) 27 (18 to 36)  26.5% 26.2% 23.3% 
Melanoma of skin 2651  1015 (520-1944) -165 (-239 to -91)  200 (68-458) 12 (-2 to 25)  25.6% 27.1% 22.8% 
Brain and meninges 2266  1216 (640-2190) -149 (-227 to -70)  205 (63-572) 3 (-11 to 17)  27.7% 28.6% 24.1% 
Unknown primary site 4030  961 (475-1816) -224 (-286 to -162)  203 (82-431) 12 (0 to 23)  22.6% 22.2% 23.5% 
Other primary malignancy 16 502  1185 (627-2234) -81 (-120 to -42)  221 (93-444) 4 (-3 to 12)  19.8% 20.4% 19.1% 
Multiple solid tumors 18 378  1746 (796-3409) 342 (305 to 379)  219 (74-545) 13 (7 to 20)  18.9% 18.8% 16.9% 
            
Total cohort 151 201  1482 (700-2986)   213 (77-490)   20.2% 20.5% 18.5% 
a Expenditures for all prescription drugs dispensed in community pharmacies (ATC A to S) 
b Expenditures for the prescription drugs mentioned in Table 2 (ATC codes available in Appendix Table X) 
c Quantile regression model adjusted for sex, age at death, number of chronic diseases, living arrangement, and education (missing 4573). β coefficients can be interpreted as the 
adjusted median difference in costs compared to lung cancer. 
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eFigure 1 – Calculation of monthly drug exposure and costs 
 
 
 
 
 
 
 
 
 
 
eTable 1 – List of Anatomical Therapeutic Chemical (ATC) codes corresponding to 
preventive drugs 
Drug class ATC code 
Drugs used in diabetes A10 
Insulin and analogues A10A 
Blood glucose lowering drugs A10B 
Vitamins A11 
Mineral supplements A12 
Calcium A12A 
Potassium A12B 
Antithrombotic agents B01A 
Vitamin K antagonists B01AA 
Heparin group B01AB 
Platelet aggregation inhibitors B01AC 
Drugs used in the treatment of hypertension C02, C03A, C03B, C07, C08 (excl. C08D), C09 
Low-ceiling diuretics C03A, C03B 
Potassium-sparing agents C03D 
Beta blocking agents C07 
Calcium channel blockers C08, excl. C08D 
ACE inhibitors C09A, C09B 
Angiotensin II antagonists C09C, C09D 
Lipid modifying agents C10 
HMG CoA reductase inhibitors C10AA 
Bisphosphonates M05BA, M05BB 
Anti-anemic preparations B03 
Iron preparations B03A 
Vitamin B12 and folic acid B03BA, B03BB 
Note: combinations of blood glucose-lowering drugs and lipid modifying agents are classified in A10B (e.g. 
combination of sitagliptin and simvastatin). 
 
eTable 2 – List of International Classification of Diseases, 10th revision (ICD-10) codes 
corresponding to solid malignancies 
Solid malignancy ICD-10 codes 
Respiratory organs (incl. lung and bronchus) C30-C39 
Esophagus and stomach  C15-C16 
Colorectal  C18-C20 
Liver and intrahepatic bile duct  C22 
Pancreas  C25 
Other digestive organs  C15-C26 
Breast  C50 
Urinary tract  C64-C68 
Male genital organs  C60-C63 
Female genital organs  C51-C58 
Melanoma of skin  C43 
Brain and meninges  C70-C71 
Unknown primary site  C80 
Other primary malignancy C00-14, C40-41, C44-49, C69, C72-C75 
Multiple tumor sites Individuals with ≥2 distinct primary sites 
 
 
 
eTable 3 – List of International Classification of Diseases, 10th revision (ICD-10) codes used to identify acute and possibly unpredictable 
deaths in older adults 
 
ICD Chapter Underlying or contributing cause of death (ICD-10 codes) Conditional argument 
1. Certain infectious and parasitic 
diseases 
A00; A01; A02; A03; A04; A05; A06; A07; A08; A09; A39; A40; A41; 
A499; A80; A81; A87; B371; B375; B377; B440; B441; B448; B449; B99 
 
2. Diseases of the blood and blood-
forming organs 
D611; D619; D649  
3. Endocrine, nutritional and metabolic 
diseases 
E86  
4. Diseases of the nervous system G000; G001; G002; G003; G009; G039; G040; G048; G049; G060; G062; 
G931; G936 
 
5. Ischaemic heart diseases and 
pulmonary heart diseases 
I21; I23; I25; I249; I249; I255; I26; I28 No history of ischemic heart disease (I20, I21, I23-
I25) or pulmonary embolism (I26) 
6. Other forms of heart disease I30; I33; I40; I461; I469  
7. Cerebrovascular diseases I60; I61; I62; I63; I64; I65; I66; I67 No history of cerebrovascular disease (I60-I69) 
8. Diseases of arteries, arterioles and 
capillaries 
I71; I72; I74; I97  
9.  Diseases of the respiratory system J069; J09; J10; J11; J12; J13; J14; J15; J18; J22; J690; J81; J851; J852; 
J93; J958; J960 
 
10.  Diseases of the digestive system K250; K251; K252; K253; K254; K255; K256; K257; K259; K260; K261; 
K263; K264; K265; K266; K269; K550; K65; K720; K810; K859 
 
11.  Diseases of the musculoskeletal 
system and connective tissue 
M726  
12.  Diseases of the genitourinary system N00; N01; N04; N10; N17; N390; N990; N998 No history of diabetes (E10-14) or renal failure (N17-
19) 
13.  Symptoms, signs and abnormal 
clinical and laboratory findings, not 
elsewhere classified 
R02; R572; R570; R571  
14.  Injury, poisoning and certain other 
consequences of external causes 
S065; S066; S068; S069; S071; S10-99; T00-T99  
15.  External causes of morbidity and 
mortality 
V00-V99; W00–W19; X60-79; X80-84  
eTable 4 – Characteristics of older adults who died with and without cancer reported as 
cause of death 
 
 
Total cohort 
(n=151 201) 
 Cancer as cause 
of death 
(n=121 217) 
No cancer as 
cause of death 
(n=29 984) 
P-value 
Sex, No. (%)  
   
<.001 
Men 83 429 (55.2)  65583 (54.1%) 17846 (59.5%)  
Women 67 772 (44.8)  55634 (45.9%) 12138 (40.5%)  
Age at time of death, years  
   
 
Mean (SD) 81.3 (8.1)  80.4 (8.0) 85.0 (7.5) <.001 
65 to 74 years 35 690 (23.6)  32449 (26.8%) 3241 (10.8%) <.001 
75 to 84 years 56 950 (37.7)  47443 (39.1%) 9507 (31.7%)  
85 to 94 years 52 474 (34.7)  37673 (31.1%) 14801 (49.4%)  
95 years and older 6087 (4.0)  3652 (3.0%) 2435 (8.1%)  
Level of educationb, No. (%)  
   
<.001 
Primary education 71 661 (48.9)  56733 (48.1%) 14928 (51.9%)  
Secondary education 57 937 (39.5)  47266 (40.1%) 10671 (37.1%)  
Tertiary education 17 030 (11.6)  13871 (11.8%) 3159 (11.0%)  
Living arrangement, No. (%)  
   
<.001 
Community 123 702 (81.8)  102376 (84.5%) 21326 (71.1%)  
Nursing home 27 499 (18.2)  18841 (15.5%) 8658 (28.9%)  
Place of death, No. (%)  
   
<.001 
Usual place of living 80,439 (53.2)  67609 (55.8%) 16170 (53.9%)  
Hospital facility 70,762 (46.8)  53608 (44.2%) 13814 (46.1%)  
Primary malignancy, No. (%)  
   
<.001 
Respiratory organs 18 435 (12.2)  17334 (14.3%) 1101 (3.7%)  
Esophagus and stomach 5014 (3.3)  4751 (3.9%) 263 (0.9%)  
Colon-rectum 16 102 (10.6)  14460 (11.9%) 1642 (5.5%)  
Liver and intrahepatic bile duct 3711 (2.5)  3486 (2.9%) 225 (0.8%)  
Pancreas 7808 (2.5)  7548 (6.2%) 260 (0.9%)  
Other digestive organs 3643 (2.4)  3387 (2.8%) 256 (0.9%)  
Breast 9920 (6.6)  8216 (6.8%) 1704 (5.7%)  
Urinary tract 10 231 (6.8)  7406 (6.1%) 2825 (9.4%)  
Male genital organs 25 642 (17.0)  19556 (16.1%) 6086 (20.3%)  
Female genital organs 6868 (4.5)  5972 (4.9%) 896 (3.0%)  
Melanoma of skin 2651 (1.8)  1915 (1.6%) 736 (2.5%)  
Brain and meninges 2266 (1.5)  1720 (1.4%) 546 (1.8%)  
Unknown primary site 4030 (2.7)  3907 (3.2%) 123 (0.4%)  
Other primary malignancy 16 502 (10.9)  4251 (3.5%) 12251 (40.9%)  
Multiple solid tumors 18 378 (12.2)  17308 (14.3%) 1070 (3.6%)  
Number of chronic comorbidities, No. (%)  
   
 
Mean (SD) 4.5 (2.8)  4.2 (2.7) 5.9 (3.0) <.001 
0 6 216 (4.1%)  5 914 (4.9%) 302 (1.0%) <.001 
1 14 242 (9.4%)  13 093 (10.8%) 1 149 (3.8%)  
2 19 570 (12.9%)  17 321 (14.3%) 2 249 (7.5%)  
3 22 039 (14.6%)  18 810 (15.5%) 3 229 (10.8%)  
4 21 529 (14.2%)  17 611 (14.5%) 3 918 (13.1%)  
≥5 67 605 (44.7%)  48 468 (40.0%) 19 137 (63.8%)  
Chronic comorbidities, No. (%)  
   
 
Hypertension 66 553 (44.0%)  51 519 (42.5%) 15 034 (50.1%) <.001 
Ischemic heart disease 50 896 (33.7%)  35 468 (29.3%) 15 428 (51.5%) <.001 
Heart failure 42 049 (27.8%)  27 563 (22.7%) 14 486 (48.3%)  
Atrial fibrillation 36 584 (24.2%)  25 531 (21.1%) 11 053 (36.9%) <.001 
Diabetes 31 279 (20.7%)  24 520 (20.2%) 6 759 (22.5%) <.001 
Cerebrovascular disease 28 730 (19.0%)  19 320 (15.9%) 9 410 (31.4%) <.001 
Cataract and other lens diseases 24 388 (16.1%)  18 789 (15.5%) 5 599 (18.7%) <.001 
 Total cohort 
(n=151 201) 
 Cancer as cause 
of death 
(n=121 217) 
No cancer as 
cause of death 
(n=29 984) 
P-value 
Sex, No. (%)  
   
<.001 
COPD, emphysema, chronic bronchitis 22 465 (14.9%)  17 349 (14.3%) 5 116 (17.1%) <.001 
Dementia 18 629 (12.3%)  12 451 (10.3%) 6 178 (20.6%) <.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eTable 5 – Use of preventive drugs during the final month of life, by cancer type 
 
 
Drugs used in 
diabetes 
Vitamins 
Mineral 
supplements 
Antithrombotic 
agents 
Drugs used in the 
treatment of 
hypertension 
Lipid modifying 
agents 
Bisphosphonates 
Anti-anemic 
preparations 
% % % % % % % % 
Respiratory organs 13.3% 8.5% 18.1% 47.1% 58.3% 20.7% 4.6% 23.7% 
Esophagus and stomach 12.6% 7.8% 14.1% 40.9% 53.6% 15.4% 1.6% 37.1% 
Colorectal 13.9% 8.6% 18.1% 43.1% 57.9% 15.2% 2.5% 34.0% 
Liver and intrahepatic bile duct 25.2% 8.8% 16.7% 43.5% 70.1% 18.2% 3.2% 23.3% 
Pancreas 28.1% 6.6% 18.8% 46.7% 60.6% 18.3% 2.4% 20.4% 
Other digestive organs 14.1% 8.3% 19.2% 42.4% 59.4% 14.5% 2.8% 29.9% 
Breast 13.3% 8.9% 25.2% 45.7% 59.8% 10.2% 9.0% 27.6% 
Urinary tract 15.2% 11.0% 17.4% 50.1% 63.8% 19.2% 2.9% 34.7% 
Male genital organs 13.5% 9.9% 17.4% 53.6% 60.4% 17.8% 3.3% 33.3% 
Female genital organs 12.7% 9.0% 21.8% 46.2% 57.1% 12.7% 4.0% 27.9% 
Melanoma of skin 14.4% 8.2% 16.4% 49.2% 63.3% 18.6% 3.5% 25.8% 
Brain and meninges 20.0% 4.6% 25.1% 41.4% 54.9% 17.8% 6.9% 15.7% 
Unknown primary site 15.3% 9.3% 20.3% 51.6% 65.0% 18.4% 4.0% 33.2% 
Other primary malignancy 13.3% 12.4% 23.5% 55.5% 65.4% 16.5% 4.3% 35.9% 
Multiple solid tumors 14.4% 8.0% 17.9% 44.6% 56.9% 16.6% 3.4% 26.9% 
Total cohort 14.9% 9.2% 19.2% 48.1% 60.1% 16.8% 3.9% 30.4% 
eTable 6 – Sensitivity analysis: use of preventive drugs during the last year of life of 
older adults (≥65 years) with cancer, after excluding individuals who died from acute 
and possibly unpredictable causes (n= 102 515) 
 
12th month 
before death 
Last month 
before death 
 
Absolute change 
Percent Percent   Percent points (95%CI) 
Drugs used in diabetes 13.8% 14.9% 
 
1.04 (0.7 to 1.3) 
Insulin and analogues 7.4% 10.2%  2.78 (2.5 to 3) 
Blood glucose-lowering drugs 8.8% 7.1%  -1.71 (-1.9 to -1.5) 
Vitamins 7.5% 8.5% 
 
0.99 (0.8 to 1.2) 
Mineral supplements 13.9% 18.5% 
 
4.55 (4.2 to 4.9) 
Calcium 10.0% 10.4%  0.41 (0.1 to 0.7) 
Potassium 4.2% 7.6%  3.32 (3.1 to 3.5) 
Antithrombotic agents 44.3% 45.6% 
 
1.25 (0.8 to 1.7) 
Vitamin K antagonists 7.2% 4.8%  -2.4 (-2.6 to -2.2) 
Heparin group 3.0% 11.2%  8.2 (8 to 8.4) 
Platelet aggregation inhibitors 35.6% 33.3%  -2.33 (-2.7 to -1.9) 
Drugs used in the treatment of hypertension 58.9% 58.3% 
 
-0.59 (-1 to -0.2) 
Low-ceiling diuretics 6.5% 5.2%  -1.31 (-1.5 to -1.1) 
Potassium-sparing agents 6.8% 11.3%  4.55 (4.3 to 4.8) 
Beta blocking agents 36.4% 36.6%  0.23 (-0.2 to 0.6) 
Calcium channel blockersd 18.5% 15.2%  -3.3 (-3.6 to -3) 
ACE inhibitors 19.7% 17.3%  -2.39 (-2.7 to -2.1) 
Angiotensin II antagonists 11.6% 9.5%  -2.14 (-2.4 to -1.9) 
Lipid modifying agents 21.6% 16.2% 
 
-5.46 (-5.8 to -5.1) 
HMG CoA reductase inhibitors 21.1% 15.6%  -5.51 (-5.8 to -5.2) 
Bisphosphonates 4.1% 3.9% 
 
-0.23 (-0.4 to -0.1) 
Anti-anemic preparations 23.5% 27.4% 
 
3.89 (3.5 to 4.3) 
Iron preparations 6.8% 10.1%  3.25 (3 to 3.5) 
Vitamin B12 and folic acid 19.3% 21.1%  1.74 (1.4 to 2.1) 
 
  
 
 
 
 
 
 
 
 
 
 
eTable 7 – Sensitivity analysis: use of preventive drugs throughout the last year of life of older adults (≥65 years) with cancer, according to 
the time between cancer diagnosis and death 
 
Time from cancer diagnosis to death 
More than 12 months  6 to 12 months  Less than 6 months  
12th month Last month 12th month Last month 12th month Last month 
Percent Percent  Percent Percent  Percent Percent  
Drugs used in diabetes 13.9% 14.4% 
 13.4% 14.3%  14.6% 16.5% 
Insulin and analogues 8.1% 9.9%  6.7% 10.1%  7.1% 10.6% 
Blood glucose-lowering drugs 8.0% 6.4%  9.3% 6.4%  10.3% 9.2% 
Vitamins 8.9% 9.4% 
 7.2% 8.5%  6.7% 8.3% 
Mineral supplements 16.1% 19.9% 
 12.3% 18.2%  12.3% 17.8% 
Calcium 11.2% 11.9%  9.0% 9.4%  9.2% 10.0% 
Potassium 5.2% 8.0%  3.6% 8.0%  3.5% 7.2% 
Antithrombotic agents 48.8% 49.0% 
 43.2% 44.7%  43.3% 47.8% 
Vitamin K antagonists 8.1% 5.8%  8.0% 4.4%  7.2% 5.7% 
Heparin group 4.1% 9.8%  1.6% 12.2%  0.5% 10.6% 
Platelet aggregation inhibitors 38.4% 36.9%  35.2% 31.4%  36.5% 36.1% 
Drugs used in the treatment of hypertension 61.3% 59.9% 
 58.7% 57.2%  60.1% 62.7% 
Low-ceiling diuretics 5.9% 4.7%  6.7% 4.9%  7.4% 6.4% 
Potassium-sparing agents 7.8% 11.2%  5.8% 11.0%  6.5% 11.2% 
Beta blocking agents 38.5% 38.7%  35.9% 35.6%  36.7% 39.1% 
Calcium channel blockersd 18.6% 15.1%  19.3% 14.8%  20.1% 18.7% 
ACE inhibitors 20.3% 18.2%  20.5% 16.7%  20.8% 20.2% 
Angiotensin II antagonists 11.6% 9.6%  12.2% 9.1%  12.4% 11.4% 
Lipid modifying agents 21.1% 16.1% 
 23.6% 15.5%  23.2% 20.3% 
HMG CoA reductase inhibitors 20.5% 15.5%  23.1% 15.1%  22.7% 19.7% 
Bisphosphonates 4.5% 4.3% 
 
3.7% 3.4% 
 
3.7% 3.6% 
Anti-anemic preparations 27.3% 30.4% 
 22.3% 27.6%  20.9% 27.9% 
Iron preparations 8.4% 10.9%  7.0% 10.8%  5.0% 10.6% 
Vitamin B12 and folic acid 22.3% 24.0%  17.9% 20.7%  18.1% 21.1% 
 
eTable 8 – Change in the costs of all prescription drugs throughout the final year of life, by cancer type 
Primary malignancy Decedents, No. 
12th  
month 
Last  
month 
 
Median difference 
(US $), 95% CI 
 
P value 
Median, US $ 
(P25-P75) 
Median, US $ 
(P25-P75) 
  
Respiratory organs 18 435 66 (20 to 162) 160 (72 to 305)  +94.3 (90.8 to 97.8)  <0.001 
Esophagus and stomach 5014 52 (16 to 124) 132 (56 to 293)  +80.0 (74.0 to 86.0)  <0.001 
Colorectal 16 102 58 (21 to 132) 119 (54 to 243)  +61.1 (58.1 to 64.0)  <0.001 
Liver and intrahepatic bile duct 3711 62 (22 to 136) 123 (55 to 247)  +60.9 (54.1 to 67.7)  <0.001 
Pancreas 7808 57 (19 to 134) 161 (74 to 329)  +104.5 (98.9 to 110.1)  <0.001 
Other digestive organs 3643 55 (19 to 133) 123 (55 to 267)  +68.1 (61.3 to 74.8)  <0.001 
Breast 9920 112 (43 to 258) 173 (73 to 330)  +61.0 (54.2 to 67.8)  <0.001 
Urinary tract 10 231 70 (27 to 152) 127 (59 to 255)  +56.5 (52.4 to 60.5)  <0.001 
Male genital organs 25 642 183 (63 to 363) 251 (110 to 452)  +67.4 (62.2 to 72.6)  <0.001 
Female genital organs 6868 71 (27 to 159) 138 (61 to 292)  +66.5 (61.1 to 71.9)  <0.001 
Melanoma of skin 2651 59 (20 to 131) 117 (56 to 229)  +58.6 (51.4 to 65.9)  <0.001 
Brain and meninges 2266 49 (12 to 125) 159 (75 to 297)  +109.6 (100.6 to 118.5)  <0.001 
Unknown primary site 4030 58 (22 to 130) 108 (52 to 209)  +50.5 (45.2 to 55.7)  <0.001 
Other primary malignancy 16 502 80 (36 to 165) 110 (55 to 216)  +30 (27.1 to 32.8)  <0.001 
Multiple solid tumors 18 378 83 (28 to 216) 180 (79 to 366)  +97.7 (93.4 to 101.9)  <0.001 
Total cohort 151 201 80 (29 to 195) 153 (68 to 314)  +73.1 (71.7 to 74.4)  <0.001 
eTable 9 – Change in the costs of preventive drugs throughout the final year of life, by cancer type 
Primary malignancy Decedents, No. 
12th  
month 
Last  
month 
 
Median difference 
(US $), 95% CI 
 
P value 
Median, US $ 
(P25-P75) 
Median, US $ 
(P25-P75) 
  
Respiratory organs 18 435 11 (0-31) 13 (3-38)  +1.89 (1.35 to 2.43)  <0.001 
Esophagus and stomach 5014 12 (1-31) 12 (3-33)  -0.16 (-1.09 to 0.77)  0.732 
Colorectal 16 102 12 (2-31) 14 (3-34)  +1.33 (0.80 to 1.86)  <0.001 
Liver and intrahepatic bile duct 3711 14 (3-34) 15 (5-38)  +1.74 (0.53 to 2.94)  <0.001 
Pancreas 7808 11 (0-29) 14 (3-42)  +2.42 (1.61 to 3.24)  <0.001 
Other digestive organs 3643 12 (2-28) 12 (3-34)  +0.71 (-0.30 to 1.73)  0.168 
Breast 9920 13 (3-34) 14 (4-35)  +0.17 (-0.51 to 0.85)  0.620 
Urinary tract 10 231 15 (4-35) 15 (5-36)  +0.23 (-0.47 to 0.94)  0.515 
Male genital organs 25 642 14 (4-32) 14 (4-32)  -0.24 (-0.65 to 0.16)  0.236 
Female genital organs 6868 13 (2-34) 15 (3-45)  +1.69 (0.76 to 2.63)  <0.001 
Melanoma of skin 2651 13 (3-31) 13 (4-34)  +0.71 (-0.58 to 2.00)  0.280 
Brain and meninges 2266 9 (0-30) 13 (2-40)  +3.59 (2.14 to 5.03)  <0.001 
Unknown primary site 4030 13 (3-30) 15 (5-35)  +1.48 (0.48 to 2.48)  <0.001 
Other primary malignancy 16 502 16 (5-34) 16 (5-35)  -0.20 (-0.71 to 0.32)  0.451 
Multiple solid tumors 18 378 12 (1-33) 13 (3-37)  +1.01 (0.48 to 1.53)  <0.001 
Total cohort 151 201 13 (3–32) 14 (4–36)  +0.78 (0.60 to 0.95)  <0.001 
  
eFigure 2 – Mean costs for preventive drugs during the final year of life, by cancer type, 
age at death and number of chronic comorbidities, in US $ 
 
eTable 10 – Sensitivity analysis: cost of preventive drugs during the final year of life, by cancer type and according to the time between 
cancer diagnosis and death 
Primary malignancy 
Total 
 Time from cancer diagnosis to death  
P value  More than 12 months 6 to 12 months Less than 6 months  
Median, US $ (P25-P75)  Median, US $ (P25-P75) Median, US $ (P25-P75) Median, US $ (P25-P75)  
Respiratory organs 205 (61-523)  219 (71-562) 228 (71-665) 192 (51-480)  <0.001 
Esophagus and stomach 199 (68-479)  217 (80-543) 209 (85-535) 187 (51-439)  <0.001 
Colorectal 209 (72-479)  217 (76-529) 213 (77-539) 204 (65-430)  <0.001 
Liver and intrahepatic bile duct 222 (82-514)  229 (89-531) 240 (99-596) 222 (76-510)  0.0305 
Pancreas 213 (69-520)  208 (69-511) 222 (64-620) 216 (70-510)  0.1337 
Other digestive organs 191 (65-426)  198 (72-472) 198 (58-513) 196 (61-422)  0.2278 
Breast 218 (81-528)  238 (88-610) 235 (92-535) 202 (72-404)  <0.001 
Urinary tract 232 (93-508)  236 (99-515) 252 (95-570) 222 (82-480)  <0.001 
Male genital organs 209 (80-450)  213 (84-461) 210 (74-449) 206 (75-428)  0.0102 
Female genital organs 239 (86-573)  252 (89-635) 279 (113-723) 230 (79-491)  <0.001 
Melanoma of skin 200 (68-458)  204 (73-468) 213 (64-545) 187 (70-414)  <0.001 
Brain and meninges 205 (63-572)  191 (47-721) 251 (76-855) 205 (67-494)  <0.001 
Unknown primary site 203 (82-431)  215 (87-448) 217 (70-617) 211 (88-437)  0.5715 
Other primary malignancy 221 (93-444)  226 (98-449) 224 (90-456) 212 (83-437)  0.009 
Multiple solid tumors 219 (74-545)  224 (78-557) 236 (81-632) 190 (52-439)  <0.001 
        
Total cohort 213 (77-490)  221 (84-509) 225 (80-560) 204 (66-459)  <0.001 
P-values were calculated with non-parametric Wilcoxon rank sum tests stratified by primary malignancy. 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
